Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Multiple sodium glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have been shown to impart significant cardiovascular and kidney benefits, but are underused in clinical practice. Both SGLT-2i and GLP-1RA were first studied as glucose-lowering drugs, which may have impeded uptake by cardiologists in the wake of proven cardiovascular efficacy. Their significant effect on cardiovascular and kidney outcomes, which are largely independent of glucose-lowering effects, must drive a broader use of these drugs. Cardiologists are 3 times more likely than endocrinologists to see patients with both type 2 diabetes and cardiovascular disease, thus they are ideally positioned to share responsibility for SGLT-2i and GLP-1RA treatment with primary care providers. In order to increase adoption, SGLT-2i and GLP-1RA must be reframed as primarily cardiovascular and kidney disease risk-reducing agents with a side effect of glucose-lowering. Coordinated and multifaceted interventions engaging clinicians, patients, payers, professional societies, and health systems must be implemented to incentivize the adoption of these medications as part of routine cardiovascular and kidney care. Greater use of SGLT-2i and GLP-1RA will improve outcomes for patients with type 2 diabetes at high risk for cardiovascular and kidney disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Self-citationCardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Self-citationEffect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Self-citationAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Rivaroxaban with or without aspirin in stable cardiovascular disease
Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709118 · Cited by 2,438
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Long-term use of ticagrelor in patients with prior myocardial infarction
Bonaca, M. P., Bhatt, D. L., Cohen, M., Steg, P. G., Storey, R. F., Jensen, E. C., Magnani, G., Bansilal, S., Fish, M. P., Im, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500857 · Cited by 1,999
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Self-citationKristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Cardiovascular outcomes with ertugliflozin in type 2 diabetes
Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004967 · Cited by 1,514
Self-citationZannad, F., Ferreira, J. P., Pocock, S. J., Anker, S. D., Butler, J., Filippatos, G., Brueckmann, M., Ofstad, A. P., Pfarr, E., Jamal, W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31824-9 · Cited by 1,408
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
Self-citationSodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., Norhammar, A., Birkeland, K. I., Jørgensen, M. E., Thuresson, M., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.029190 · Cited by 813
Self-citationZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038868 · Cited by 781
Self-citationSabatine, M. S., Leiter, L. A., Wiviott, S. D., Giugliano, R. P., Deedwania, P., De Ferrari, G. M., Murphy, S. A., Kuder, J. F., Gouni-Berthold, I., Lewis, B. S., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30313-3 · Cited by 603
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s010 · Cited by 471
Das, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Januzzi, J. L., Kalyani, R. R., Kosiborod, M., Magwire, M., Morris, P. B., Neumiller, J. J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.037 · Cited by 466
Self-citationGlucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
Hinnen, D. (2017) · Diabetes Spectrum · doi:10.2337/ds16-0026 · Cited by 394
Zinman, B., Bhosekar, V., Busch, R., Holst, I., Ludvik, B., Thielke, D., Thrasher, J., Woo, V., & Philis-Tsimikas, A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30066-x · Cited by 376
Ticagrelor in patients with stable coronary disease and diabetes
Steg, P. G., Bhatt, D. L., Simon, T., Fox, K., Mehta, S. R., Harrington, R. A., Held, C., Andersson, M., Himmelmann, A., Ridderstråle, W., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908077 · Cited by 365
Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., Budaj, A. J., Diaz, R., Goodman, S. G., Hanotin, C., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30158-5 · Cited by 315
Ludvik, B., Frías, J. P., Tinahones, F. J., Wainstein, J., Jiang, H., Robertson, K. E., García-Pérez, L.-E., Woodward, D. B., & Milicevic, Z. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30023-8 · Cited by 266
Patorno, E., Pawar, A., Franklin, J. M., Najafzadeh, M., Déruaz-Luyet, A., Brodovicz, K. G., Sambevski, S., Bessette, L. G., Santiago Ortiz, A. J., Kulldorff, M., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.039177 · Cited by 215
Azoulay, L., & Suissa, S. (2017) · Diabetes Care · doi:10.2337/dc16-1943 · Cited by 195
Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0800-2 · Cited by 171
Bhatt, D. L., Eikelboom, J. W., Connolly, S. J., Steg, P. G., Anand, S. S., Verma, S., Branch, K. R. H., Probstfield, J., Bosch, J., Shestakovska, O., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.046448 · Cited by 158
Arnold, S. V., Inzucchi, S. E., Tang, F., McGuire, D. K., Mehta, S. N., Maddox, T. M., Goyal, A., Sperling, L. S., Einhorn, D., Wong, N. D., et al. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317729252 · Cited by 144
Self-citationArnold, S. V., de Lemos, J. A., Rosenson, R. S., Ballantyne, C. M., Liu, Y., Mues, K. E., Alam, S., Elliott-Davey, M., Bhatt, D. L., Cannon, C. P., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.041730 · Cited by 130
Neuen, B. L., Arnott, C., Perkovic, V., Figtree, G., de Zeeuw, D., Fulcher, G., Jun, M., Jardine, M. J., Zoungas, S., Pollock, C., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14226 · Cited by 78
Hamid, A., Vaduganathan, M., Oshunbade, A. A., Ayyalasomayajula, K. K., Kalogeropoulos, A. P., Lien, L. F., Shafi, T., Hall, M. E., & Butler, J. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000864 · Cited by 57
Gunawan, F., Nassif, M. E., Partridge, C., Ahmad, T., Kosiborod, M., & Inzucchi, S. E. (2020) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000195 · Cited by 28
Cited by
Development and validation of the American Heart Association’s PREVENT equations
Khan, S. S., Matsushita, K., Sang, Y., Ballew, S. H., Grams, M. E., Surapaneni, A., Blaha, M. J., Carson, A. P., Chang, A. R., Ciemins, E., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067626 · Cited by 1,234
Gliflozins in the Management of Cardiovascular Disease
Braunwald, E. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2115011 · Cited by 266
Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Kelsey, M. D., Nelson, A. J., Green, J. B., Granger, C. B., Peterson, E. D., McGuire, D. K., & Pagidipati, N. J. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.046 · Cited by 106
Self-citationNelson, A. J., O’Brien, E. C., Kaltenbach, L. A., Green, J. B., Lopes, R. D., Morse, C. G., Al-Khalidi, H. R., Aroda, V. R., Cavender, M. A., Gaynor, T., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.48030 · Cited by 78
Self-citationKalyani, R. R., Allende-Vigo, M. Z., Antinori-Lent, K. J., Close, K. L., Das, S. R., Deroze, P., Edelman, S. V., El Sayed, N. A., Kerr, D., Neumiller, J. J., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad745 · Cited by 25
Metadata
- Authors
- Nelson, A. J., Pagidipati, N. J., Aroda, V. R., Cavender, M. A., Green, J. B., Lopes, R. D., Al-Khalidi, H., Gaynor, T., Kaltenbach, L. A., Kirk, J. K., Lingvay, I., Magwire, M. L., O’Brien, E. C., Pak, J., Pop-Busui, R., Richardson, C. R., Reed, M., Senyucel, C., Webb, L., McGuire, D. K., & Granger, C. B.
- Venue
- Circulation
- Published
- 2021-07-06
- Volume
- 144
- Issue
- 1
- Pages
- 74-84
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W3178245457
- Cited by
- 79
- References
- 48
- FWCI
- 7.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.